Disease · MONDO_0003960

pulmonary large cell neuroendocrine carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pulmonary large cell neuroendocrine carcinoma. Diseases, record MONDO_0003960. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003960

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pulmonary large cell neuroendocrine carcinoma; Open Targets
Open Targets ID: MONDO_0003960; Open Targets
Other names: LCNEC of the lung, large cell lung carcinoma with neuroendocrine differentiation, large cell lung neuroendocrine carcinoma, large cell neuroendocrine carcinoma of lung, large cell neuroendocrine carcinoma of the lung, lung large cell neuroendocrine carcinoma; Open Targets
Disease Ontology: DOID:6658; Disease Ontology
NCI Thesaurus: C5672; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 8 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BENMELSTOBART	CHEMBL5315042	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OBRIXTAMIG	CHEMBL6068151	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PLATINUM	CHEMBL1235478	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NENDRATAREOTIDE UZATANSINE	CHEMBL4650335	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
FLT4	Vascular endothelial growth factor receptor 3	1	Vascular endothelial growth factor receptor 3 inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	1	Vascular endothelial growth factor receptor 2 inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	1	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
TOP2A	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
TOP2B	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7155	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02936323	PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers	Phase 1/2	89	2021-12-14	Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma	NENDRATAREOTIDE UZATANSINE	Its record names the disease	ClinicalTrials.gov
NCT06393816	FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum	Phase 2	80		Large Cell Neuroendocrine Carcinoma of the Lung	CARBOPLATIN, CISPLATIN, DURVALUMAB, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov
NCT07561645	A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung	Phase 2	75		Large Cell Neuroendocrine Carcinoma of the Lung	OBRIXTAMIG	Its record names the disease	ClinicalTrials.gov
NCT06418087	Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)	Phase 2	49		Pulmonary Large-cell Neuroendocrine Carcinoma	CARBOPLATIN, DURVALUMAB, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov
NCT07510594	A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC	Phase 2	48		Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma	BENMELSTOBART, CATEQUENTINIB, ETOPOSIDE, PLATINUM	Its record names the disease	ClinicalTrials.gov
NCT05262985	Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study	Phase 2	22		Patients With Advanced Treatment Naive LCNEC	CARBOPLATIN, CISPLATIN, DURVALUMAB, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
42526918	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003960

GET https://conductscience.org/api/diseases/v1/MONDO_0003960/drugs

API reference For AI assistants